KP-CoT-23 (CCDC83) is a novel immunogenic cancer/testis antigen in colon cancer.
Int J Oncol
; 41(5): 1820-6, 2012 Nov.
Article
en En
| MEDLINE
| ID: mdl-22923163
ABSTRACT
Cancer/testis (CT) antigens are considered target molecules for cancer immunotherapy. To identify novel CT antigens, immunoscreening of a testicular cDNA library was performed using serum obtained from a colon cancer patient who was immunized with a new dendritic cell vaccine. We isolated 64 positive cDNA clones comprised of 40 different genes, designated KP-CoT-1 through KP-CoT-40. Three of these putative antigens, including KP-CoT-23 (CCDC83), had testis-specific expression profiles in the Unigene database. RT-PCR analysis showed that the expression of 2 KP-Cot-23 variants was restricted to the testis in normal adult tissues. In addition, KP-CoT-23 variants were frequently expressed in a variety of tumors and cancer cell lines, including colon cancer. A serological western blot assay showed IgG antibodies to the KP-CoT-23 protein in 26 of 37 colon cancer patients and in 4 of 21 healthy patients. These data suggest that KP-CoT-23 is a novel CT antigen that may be useful for the diagnosis and immunotherapy of cancer.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Testículo
/
Neoplasias del Colon
/
Proteínas de la Membrana
/
Antígenos de Neoplasias
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Int J Oncol
Asunto de la revista:
NEOPLASIAS
Año:
2012
Tipo del documento:
Article
Pais de publicación:
GR
/
GRECIA
/
GREECE
/
GRÉCIA